TMS Enhancement of Visual Plasticity in Schizophrenia

Overview

The major goal is to determine if Transcranial magnetic stimulation (TMS) enhances visual plasticity in schizophrenia. TMS sessions (sham/placebo and real TMS) will be conducted before two MRI scans with two weeks in-between to assess whether TMS stimulation to the visual cortex will enhance visual plasticity in patients with schizophrenia-spectrum disorders. This project may provide a better understanding of the underlying neurobiological mechanisms responsible for learning and memory deficits in schizophrenia.

Full Title of Study: “Testing TMS Enhancement of Visual Plasticity in Schizophrenia”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Crossover Assignment
    • Primary Purpose: Basic Science
    • Masking: Double (Participant, Investigator)
  • Study Primary Completion Date: July 16, 2019

Detailed Description

Learning and memory impairments are commonly observed in schizophrenia spectrum disorders. Alterations in "long-term potentiation" (LTP), a basic mechanism underlying learning and memory, may explain this impairment. This project will assess fMRI visual plasticity, thought to reflect LTP, in participants with and without schizophrenia spectrum disorders. Previous studies have shown that visual plasticity is impaired in schizophrenia. The major goal is to determine if Transcranial magnetic stimulation (TMS) enhances visual plasticity in schizophrenia. Transcranial magnetic stimulation (TMS) provides a non-invasive means for altering brain electrical neural activity. TMS sessions (sham/placebo and real TMS) will be conducted before two MRI scans with two weeks in-between to assess whether TMS stimulation to the visual cortex will enhance visual plasticity in patients with schizophrenia-spectrum disorders. This project may provide a better understanding of the underlying neurobiological mechanisms responsible for learning and memory deficits in schizophrenia.

Interventions

  • Device: Transcranial Magnetic Stimulation
    • Transcranial Magnetic Stimulation

Arms, Groups and Cohorts

  • Active Comparator: TMS
    • rTMS
  • Sham Comparator: Sham TMS
    • A sham coil will be used. This condition controls for the auditory artifacts induced by rTMS.

Clinical Trial Outcome Measures

Primary Measures

  • fMRI BOLD response of visual plasticity
    • Time Frame: 4 hours
    • fMRI BOLD response of visual plasticity

Secondary Measures

  • MRS assessment of glutamate
    • Time Frame: 4 hours
    • occipital cortical glutamate levels

Participating in This Clinical Trial

Inclusion Criteria

1. age: 18-65, 2. no neurological illness, head trauma, or major medical illness, 3. not pregnant or nursing, 4. no contraindication for TMS or MRI scanning, 5. no current substance abuse/dependence. Healthy controls will have no DSM-5 diagnosis and no first-degree relatives with a psychotic disorder. Inclusion criteria for patients includes: 1. DSM-5 diagnosis of schizophreniform, schizophrenia or schizoaffective and competent to sign an informed consent, 2. not currently taking other medications that affects brain structure (e.g. steroids), 3. less than 12 months antipsychotic exposure and on the same psychotropic medications for 4 weeks prior to study, 4. not be taking clozapine (due to its effects on NMDA receptors and increase of seizure threshold), 5. clinically stable (i.e. no change in psychotic symptoms for at least 4 weeks). Exclusion Criteria:

1. age outside of 18-65, 2. neurological illness, head trauma, or major medical illness, 3. pregnant or nursing, 4. contraindication for TMS or MRI scanning, 5. current substance abuse/dependence, 6. currently taking medications that affects brain structure (e.g. steroids). Healthy controls with a DSM-5 diagnosis and/or a first-degree relative with a psychotic disorder. Participants with schizophrenia that are not competent to sign an informed consent, have more than 12 months antipsychotic exposure, not on the same psychotropic medications for 4 weeks prior to study, taking clozapine, and not clinically stable (i.e.a change in psychotic symptoms for at least 4 weeks).

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: 65 Years

Are Healthy Volunteers Accepted: Accepts Healthy Volunteers

Investigator Details

  • Lead Sponsor
    • University of Maryland, Baltimore
  • Provider of Information About this Clinical Study
    • Principal Investigator: Laura Rowland, Associate Professor – University of Maryland, Baltimore
  • Overall Official(s)
    • Laura M Rowland, PhD, Principal Investigator, University of Maryland, Baltimore

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.